Coya Therapeutics, Inc.

NasdaqCM:COYA Stock Report

Market Cap: US$123.4m

Coya Therapeutics Future Growth

Future criteria checks 0/6

Coya Therapeutics's earnings are forecast to decline at 9.3% per annum while its annual revenue is expected to grow at 1.5% per year. EPS is expected to decline by 11.9% per annum.

Key information

-9.3%

Earnings growth rate

-11.94%

EPS growth rate

Biotechs earnings growth25.3%
Revenue growth rate1.5%
Future return on equityn/a
Analyst coverage

Good

Last updated12 Jun 2026

Recent future growth updates

Recent updates

Analysis Article • Sep 16

Is Coya Therapeutics (NASDAQ:COYA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Apr 04

We Think Coya Therapeutics (NASDAQ:COYA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Oct 29

Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 13

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Summary Coya Therapeutics is developing treatments for neurodegenerative diseases, with its lead drug COYA 302 showing promising early results in ALS trials. Despite recent delays, the adverse investor reaction presents an investment opportunity as the company progresses on its pipeline development. The partnership with Dr. Reddy's Labs validates COYA 302 and provides a mechanism for rapid commercial scaling upon FDA approval. Upcoming presentations and potential new partnerships could act as catalysts for share price appreciation. Read the full article on Seeking Alpha
Analysis Article • Mar 26

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, Coya...
Seeking Alpha • Feb 13

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Summary Coya Therapeutics has strengthened its strategic positioning with a licensing deal with Dr. Reddy's, providing significant financial derisking and expanding its pipeline. The company has proven its ability to execute business development activities and is in a strong position for upcoming clinical success and potential regulatory approval. Multiple catalysts such as Alzheimer's topline data or additional business development deals could move shares higher. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Summary Coya Therapeutics is targeting inflammation in neurological diseases by modulating the function of regulatory T cells. The company has decided to put its lead asset, COYA 101, on hold due to cash problems and focus on other assets in early stage studies. Preliminary data from COYA 302 in ALS and COYA 301 in Alzheimer's disease show promising results, but the company's low cash balance poses a risk. Read the full article on Seeking Alpha
Analysis Article • Sep 06

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • May 17

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Earnings and Revenue Growth Forecasts

NasdaqCM:COYA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202820-19N/AN/A2
12/31/20275-32N/AN/A6
12/31/20262-31N/AN/A7
3/31/20268-21-16-14N/A
12/31/20258-21-12-11N/A
9/30/20254-18-13-12N/A
6/30/20250-20-16-16N/A
3/31/20254-17-15-15N/A
12/31/20244-15-10-10N/A
9/30/202410-11-10-10N/A
6/30/202410-10-7-7N/A
3/31/20246-10-6-5N/A
12/31/20236-8-12-11N/A
9/30/2023N/A-12-12-11N/A
6/30/2023N/A-13-11-11N/A
3/31/2023N/A-13-10-9N/A
12/31/2022N/A-12-8-7N/A
9/30/2022N/A-11-6-6N/A
6/30/2022N/A-8-6-6N/A
3/31/2022N/A-6-5-5N/A
12/31/2021N/A-5-4-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: COYA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: COYA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: COYA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: COYA's revenue (1.5% per year) is forecast to grow slower than the US market (12.9% per year).

High Growth Revenue: COYA's revenue (1.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if COYA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 05:01
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coya Therapeutics, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Keay NakaeChardan Capital Markets, LLC
Ilya ZubkovFreedom Broker